Pluri’s Cellav Lists Two Regenerative Products for 2026 U.S. Launch in $90B Aesthetics Market
PLUR•Cellav, Pluri’s consumer-health subsidiary, completed U.S. cosmetic listings for two regenerative products—Regenativo+ and Placento+—for a 2026 commercial launch. Both DUO-format formulations showed statistically significant improvements (p<0.05) in skin elasticity, firmness and discoloration during clinical validation, positioning Cellav for entry into a $90 billion medical aesthetics market by 2030.
1. U.S. Cosmetic Listing and Product Details
Cellav Health and Aesthetics completed U.S. cosmetic product listings for Regenativo+ and Placento+, enabling a planned 2026 commercial launch. Both products employ a DUO format—lyophilized powder plus booster vial—designed for professional, topical use after aesthetic procedures, and clinical trials (p<0.05) confirmed improvements in skin elasticity, firmness, vascular tone and discoloration without significant adverse events.
2. Market Opportunity and Distribution Plans
Entry targets the U.S. medical aesthetics market, projected to reach $90 billion by 2030. Cellav is in active discussions with U.S. distributors and clinic networks while advancing strategic partnerships across the United States, United Kingdom and other international markets to secure initial orders and expand adoption among licensed aesthetic professionals.
3. Technology Platform and Strategic Positioning
Pluri’s proprietary 3D cell-expansion platform underpins Cellav’s scalable manufacturing and clinical development for regenerative aesthetics and longevity. This launch establishes a commercial foothold for further portfolio expansion and positions the company to capture market share in high-margin consumer health and longevity segments.
